# Podophyllotoxin (Podophyllum hexandrum / Podophyllum peltatum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/podophyllotoxin-podophyllum-hexandrum-podophyllum-peltatum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Podophyllum hexandrum lignan, PPT, Podofilox precursor, (-)-Podophyllotoxin, Podophyllinic acid lactone, Bankakri extract constituent, C₂₂H₂₂O₈

## Overview

Podophyllotoxin (C₂₂H₂₂O₈, MW 414.41) is a tetracyclic lignan that exerts antimitotic activity by binding directly to tubulin at the colchicine-binding site, preventing microtubule polymerization and arresting cells in metaphase. Its greatest clinical significance lies not in direct therapeutic use but as the biosynthetic precursor to the semisynthetic epipodophyllotoxins etoposide and teniposide, which are FDA-approved topoisomerase II inhibitors used in treatment of small-cell lung cancer, testicular cancer, and lymphomas.

## Health Benefits

- **Antimitotic Activity**: Podophyllotoxin binds tubulin at the colchicine site with high affinity, disrupting microtubule dynamics and halting cell division at metaphase, demonstrating IC₅₀ values as low as 0.051 µM against HepG2 hepatocellular carcinoma and MOLT-3 leukemia cell lines in vitro.
- **Precursor to Anticancer Pharmaceuticals**: Chemical modification of podophyllotoxin at the C-4 position yields etoposide and teniposide, semisynthetic derivatives that inhibit topoisomerase II and are cornerstone agents in oncology regimens for testicular cancer, small-cell lung cancer, and non-Hodgkin lymphoma.
- **Topical [Antiviral](/ingredients/condition/immune-support)/Antiproliferative (Wart Treatment)**: The synthetic analog podofilox (podophyllotoxin 0.5% cream or solution) is FDA-approved for treatment of external genital condylomata acuminata (HPV-induced warts) and molluscum contagiosum, causing localized cytotoxic necrosis of virally infected proliferating tissue.
- **COX-2 Inhibition**: Molecular docking and biochemical assays indicate podophyllotoxin inhibits cyclooxygenase-2 (COX-2) with an IC₅₀ of approximately 10.49 ± 0.61 µM, suggesting potential [anti-inflammatory](/ingredients/condition/inflammation) activity beyond antimitotic effects, though this has not been clinically validated.
- **Topoisomerase I/II Modulation**: Podophyllotoxin and related lignans such as diphyllin show binding energies of −9.45 kcal/mol (Topo II) and −9.95 kcal/mol (COX-2 for diphyllin) in silico, indicating multi-target engagement relevant to anticancer scaffold design.
- **Anticancer Scaffold for Drug Discovery**: Related lignans including 5-methoxypodophyllotoxin, desoxypodophyllotoxin, and 4′-demethylpodophyllotoxin exhibit nanomolar cytotoxicity against diverse cancer cell lines, serving as pharmacophoric templates for next-generation anticancer agent synthesis.
- **Antifungal and Antiviral Potential**: Preclinical data suggest podophyllotoxin and congeners exhibit activity against certain fungi and viruses, including potential ACE2 binding affinity (molecular docking), though these applications remain entirely investigational and lack clinical evidence.

## Mechanism of Action

Podophyllotoxin binds to the colchicine-binding site on β-tubulin heterodimers, preventing their polymerization into microtubules and thereby blocking mitotic spindle formation; this arrests dividing cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis through spindle assembly checkpoint activation. Its tetracyclic core structure—comprising fused rings A through D with four defined chiral centers (C1, C2, C3, C4), a γ-lactone, a methylenedioxy group, and three methoxy substituents—is essential for tubulin binding, and stereochemical inversion at C1 in semisynthetic derivatives fundamentally redirects the mechanism toward topoisomerase II inhibition rather than tubulin destabilization. Biosynthetically, the compound is derived from (-)-matairesinol via a series of oxidative steps catalyzed by cytochrome P450 enzymes including CYP719A23 (pluviatolide methylenedioxy bridge formation) and sericoisolariciresinol dehydrogenase, with the final aromatization and hydroxylation steps completing the characteristic aryltetralin skeleton. Secondary targets identified by in silico and biochemical assays include topoisomerase I and II, [COX-2](/ingredients/condition/inflammation), and ACE2, suggesting polypharmacological potential that informs analog development.

## Clinical Summary

No published human clinical trials have evaluated systemic podophyllotoxin administration due to its known toxicity profile; all direct human evidence is limited to topical podofilox (0.5% solution or cream) for HPV-related genital warts, where multicenter RCTs have demonstrated clearance rates of approximately 45–88% with patient-applied twice-daily treatment over 4-week cycles. The semisynthetic derivatives etoposide and teniposide—structurally derived from podophyllotoxin—are extensively studied in phase III oncology trials, forming the evidentiary backbone of the compound's clinical relevance, but this evidence cannot be extrapolated to podophyllotoxin itself due to fundamentally different mechanisms of action and pharmacokinetic profiles. In vitro antiproliferative outcomes such as IC₅₀ of 6.46 ± 1.79 µM against A549 cells and outperformance of 5-fluorouracil and etoposide at 100 µM concentrations are hypothesis-generating but not clinically actionable without human pharmacokinetic and efficacy data. Confidence in podophyllotoxin's direct clinical utility as an oral or systemic agent is currently very low; its primary value remains as a pharmaceutical precursor and topical antimitotic scaffold.

## Nutritional Profile

Podophyllotoxin is a secondary metabolite lignan, not a nutritional compound; it contributes no caloric, macronutrient, or micronutrient value in any biologically relevant sense. In dried Podophyllum hexandrum rhizomes, podophyllotoxin occurs at approximately 12.8 mg/g dry weight, accompanied by related lignans including 4′-demethylpodophyllotoxin (~1.35 mg/g), desoxypodophyllotoxin (~0.05 mg/g), and trace quantities of diphyllin and glycoside conjugates such as diphyllin O-glucoside. The plant matrix also contains flavonoids, quercetin derivatives, tannins, and resinous components collectively termed 'podophyllin resin,' which comprises 3–8% of rhizome dry weight; however, none of these constituents are consumed as dietary nutrients. Oral bioavailability data for podophyllotoxin are not established in humans due to the absence of clinical pharmacokinetic trials, though its lipophilicity (logP approximately 1.6) and molecular weight (414.41 Da) suggest moderate membrane permeability that is offset by high systemic toxicity precluding therapeutic oral administration.

## Dosage & Preparation

- **Topical Podofilox (0.5% Solution or Cream)**: The only approved human-use formulation; applied twice daily for 3 consecutive days per week, for up to 4 cycles (FDA-approved for external genital warts); not to be used on mucous membranes or perianal tissue without physician direction.
- **Podophyllin Resin (10–25% in Compound Tincture of Benzoin)**: A crude extract applied by healthcare providers in-office to condylomata acuminata; must be washed off after 1–4 hours; not for self-application due to systemic absorption risk.
- **Oral Dosage**: No established safe or therapeutic oral dose exists for podophyllotoxin; systemic administration is not recommended outside closely monitored investigational settings due to severe neurotoxicity, myelosuppression, and teratogenicity.
- **Botanical Extract (Standardized Rhizome)**: Podophyllin resin from Podophyllum hexandrum contains approximately 12.8 mg/g podophyllotoxin in dried rhizome; no standardized dietary supplement dose has been established or validated for safe human use.
- **Pharmaceutical Precursor (Industrial)**: Extracted via solvent-based methods (ethanol/methanol) from Podophyllum rhizomes or endophytic fungal fermentation broth; yields optimized by cold treatment (10°C), glucose supplementation (60 g/L), nitrogen (60 mM), and phosphate (1.25 mM) manipulation in fungal culture systems.
- **Standardization**: Pharmaceutical-grade podophyllotoxin used in derivative synthesis is typically >95% purity by HPLC; no supplemental standardization thresholds have been defined by regulatory bodies.

## Safety & Drug Interactions

Podophyllotoxin carries a serious systemic toxicity profile that absolutely contraindicates oral or parenteral self-administration; documented toxic effects in historical poisoning cases and clinical reports include peripheral neuropathy, myelosuppression (pancytopenia), hepatotoxicity, nephrotoxicity, seizures, and multi-organ failure following ingestion or excessive topical absorption. Topical podofilox (0.5%) is comparatively safe when used as directed but commonly causes local reactions including burning, erosion, pain, pruritus, and erythema at the application site; systemic absorption from topical use is generally low but increases with large treatment areas or mucosal application. Podophyllotoxin and its derivatives are absolutely contraindicated in pregnancy due to demonstrated teratogenicity and fetotoxicity (Category X considerations); it is also contraindicated during lactation, in immunocompromised patients with large lesion burdens, and in patients with diabetes or peripheral vascular disease due to wound-healing impairment. Drug interactions have not been systematically characterized for the parent compound, but based on mechanism, concurrent use with other antimitotic agents (vinca alkaloids, taxanes), myelosuppressants, or topoisomerase inhibitors (etoposide) would be expected to produce additive toxicity; co-administration with CYP3A4 inhibitors could theoretically increase systemic exposure.

## Scientific Research

The clinical evidence base for podophyllotoxin itself is narrow and largely confined to its topical derivative podofilox, which has been evaluated in multiple randomized controlled trials for genital wart clearance with established efficacy and safety profiles; however, rigorous large-scale RCT data specifically for the parent compound podophyllotoxin as a standalone therapeutic agent are absent from the peer-reviewed literature. The vast majority of mechanistic data derives from in vitro cell-line studies, including IC₅₀ determinations against A549 (lung), HT-29 (colon), HepG2 (liver), MOLT-3 (leukemia), and BGC-823 (gastric) cancer cells, with potency ranging from 0.051 µM to 43.74 ± 5.13 µM depending on cell line and assay conditions; these preclinical findings establish pharmacological plausibility but cannot directly inform human dosing or therapeutic outcomes. The clinical evidence for its semisynthetic derivatives etoposide and teniposide is robust, including dozens of phase II and III RCTs and systematic reviews supporting their use in oncology, but this evidence is attributable to the structurally modified derivatives—not podophyllotoxin itself. Endophytic fungal production and biosynthetic optimization studies (e.g., 3.33-fold yield increase at 10°C chilling; glucose elicitation at 60 g/L) represent a growing biotechnological literature but remain at the laboratory scale with no translational clinical output to date.

## Historical & Cultural Context

Podophyllum peltatum rhizomes were used extensively by numerous Native American peoples—including the Cherokee, Iroquois, and Penobscot—as a cathartic, anthelmintic, and topical caustic for wart and skin lesion removal, with oral preparations also employed as emetics and purgatives despite recognized toxicity. In Ayurvedic and Unani traditional medicine systems, Podophyllum hexandrum (known as 'Bankakri' in Hindi) was similarly applied as a purgative and topical treatment for skin conditions, and the plant held importance in traditional Himalayan folk medicine for treating jaundice, fevers, and rheumatic conditions. The chemical identity of podophyllotoxin was first elucidated in the 1880s and more precisely characterized structurally in the 1930s–1950s, with Hartwell and Schrecker conducting foundational isolation work in the mid-twentieth century that led directly to the semisynthetic development of etoposide by Sandoz in the 1960s–70s. The World Health Organization listed Podophyllum hexandrum as a threatened species in CITES Appendix II due to intensive rhizome harvesting driven by pharmaceutical demand, prompting global research into endophytic fungal biosynthesis and plant cell culture as sustainable production alternatives.

## Synergistic Combinations

In pharmaceutical contexts, podophyllotoxin-derived etoposide is synergistically combined with cisplatin and bleomycin (BEP regimen) for testicular cancer, and with carboplatin for small-cell lung cancer, leveraging complementary DNA damage mechanisms (topoisomerase II inhibition plus platinum crosslinking); however, these synergies apply to the semisynthetic derivative, not podophyllotoxin itself. Biosynthetically, podophyllotoxin accumulation in endophytic fungi is synergistically enhanced by combining elicitor strategies—cold stress (10°C), carbon source supplementation (60 g/L glucose), and optimized nitrogen/phosphate ratios—suggesting that production synergy informs sustainable pharmaceutical supply rather than therapeutic co-administration. At the preclinical research level, diphyllin (a co-occurring lignan in Podophyllum extracts) demonstrates complementary [COX-2](/ingredients/condition/inflammation) inhibition (IC₅₀ binding energy −9.95 kcal/mol) alongside podophyllotoxin's tubulin-targeting activity, indicating potential multi-target synergy within the native plant lignan complex that warrants further investigation.

## Frequently Asked Questions

### What is podophyllotoxin used for medically?

Podophyllotoxin is used topically as podofilox (0.5% solution or cream) for FDA-approved treatment of external genital warts caused by HPV, achieving clearance rates of approximately 45–88% in clinical studies. More significantly, it serves as the chemical precursor to the semisynthetic anticancer drugs etoposide and teniposide, which are topoisomerase II inhibitors used in chemotherapy regimens for testicular cancer, small-cell lung cancer, and lymphomas. Systemic administration of podophyllotoxin itself is not clinically practiced due to severe toxicity.

### Is podophyllotoxin safe to take orally or as a supplement?

No—podophyllotoxin is not safe for oral supplementation and is not classified as a dietary supplement ingredient by any major regulatory authority. Historical accidental ingestion and overdose cases have documented life-threatening toxicity including peripheral neuropathy, bone marrow suppression, liver damage, kidney failure, and seizures. Its potent antimitotic activity at micromolar concentrations (IC₅₀ as low as 0.051 µM in cancer cells) indicates it has no therapeutic window suitable for oral self-administration.

### How does podophyllotoxin differ from etoposide?

Podophyllotoxin binds directly to tubulin at the colchicine site, preventing microtubule polymerization and arresting cells in metaphase—an action analogous to colchicine itself. Etoposide is a semisynthetic C-4 epimer derivative of podophyllotoxin that has lost tubulin-binding affinity due to stereochemical inversion and instead acts as a topoisomerase II inhibitor, stabilizing the enzyme-DNA cleavage complex and causing double-strand DNA breaks. This structural modification dramatically changes the mechanism, pharmacokinetics, toxicity profile, and clinical utility of the two compounds.

### What plant does podophyllotoxin come from?

Podophyllotoxin is extracted primarily from the rhizomes and roots of Podophyllum hexandrum (Himalayan mayapple), native to India, Nepal, and China, and Podophyllum peltatum (American mayapple), native to eastern North America. Rhizome concentrations reach approximately 12.8 mg/g dry weight in P. hexandrum. Due to overharvesting threatening wild populations—P. hexandrum is listed in CITES Appendix II—researchers are developing sustainable biotechnological production using endophytic fungi isolated from these plants and optimizing fermentation conditions.

### What are the side effects of podofilox (podophyllotoxin 0.5%)?

Topical podofilox at 0.5% concentration most commonly causes local application-site reactions including burning, pain, erosion, inflammation, itching, and bleeding at the treated wart site; these effects are generally self-limiting and resolve between treatment cycles. Systemic toxicity from topical use at recommended doses is rare when applied to small treatment areas (<10 cm²) as directed. Podofilox is absolutely contraindicated in pregnancy due to teratogenicity risk, and should not be applied to internal mucosal surfaces, open wounds, or in immunocompromised patients with extensive lesion burden without close medical supervision.

### What is the mechanism by which podophyllotoxin stops cancer cells from dividing?

Podophyllotoxin binds to tubulin proteins at the colchicine binding site with high affinity, disrupting the formation and stability of microtubules that are essential for cell division. By preventing microtubule dynamics, podophyllotoxin halts cancer cells at metaphase, effectively blocking the mitotic process. This antimitotic mechanism is why it has been developed into pharmaceutical anticancer agents with IC₅₀ values as low as 0.051 µM against certain cancer cell lines.

### Why is podophyllotoxin used as a starting material for developing new anticancer drugs rather than as a direct medication?

Podophyllotoxin's natural structure limits its pharmaceutical properties, prompting chemists to modify it—particularly at the C-4 position—to create more stable, selective, and less toxic derivatives. These chemical modifications have led to FDA-approved anticancer medications like etoposide and teniposide that retain the antimitotic activity while improving safety profiles and bioavailability. This semi-synthetic approach balances the potent cancer-fighting properties of the natural compound with the requirements for safe clinical use.

### How do the two Podophyllum species (P. hexandrum and P. peltatum) compare in terms of podophyllotoxin content?

Podophyllum hexandrum (Indian podophyllum) and Podophyllum peltatum (American podophyllum) both contain podophyllotoxin but differ in concentration and other lignan profiles. P. hexandrum is often preferred in pharmaceutical and research applications due to higher and more consistent podophyllotoxin yields, making it more economically viable for drug precursor extraction. Geographic sourcing and species selection significantly impact the efficiency of extracting this valuable compound for pharmaceutical development.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*